TY - JOUR AU - Yoshida, K. AU - Yamaguchi, K. AU - Okumura, N. AU - Tanahashi, T. AU - Kodera, Y. PY - 2015 DA - 2015// TI - Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification JO - Gastric Cancer VL - 19 UR - https://doi.org/10.1007/s10120-015-0575-z DO - 10.1007/s10120-015-0575-z ID - Yoshida2015 ER - TY - STD TI - Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. Nature Publishing Group; 2003;22:6570–8. ID - ref2 ER - TY - STD TI - Rubin I, Yarden Y. The Basic Biology of HER2. Annals of Oncology. Oxford University Press; 2001;12:S3–S8. ID - ref3 ER - TY - STD TI - Dang H-Z, Yu Y, Jiao S-C. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. WJG. 2012;18:2402–7. ID - ref4 ER - TY - STD TI - Jørgensen JT, Hersom M. HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature. J Cancer. 2012;3:137–44. ID - ref5 ER - TY - STD TI - Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9. ID - ref6 ER - TY - STD TI - Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. A published erratum appears in Lancet. 2010;376(9749):1302. ID - ref7 ER - TY - STD TI - Han D-S, Suh Y-S, Kong S-H, Lee H-J, Im S-A, Bang Y-J, et al. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol. Wiley-Blackwell; 2013;107:511–6. ID - ref8 ER - TY - STD TI - Satoh S, Okabe H, Teramukai S, Hasegawa S, Ozaki N, Ueda S, et al. Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastric Cancer. 2011;15:61–9. ID - ref9 ER - TY - STD TI - Yoshida K, Yamaguchi K, Okumura N, Osada S, Takahashi T, Tanaka Y, et al. The Roles of Surgical Oncologists in the New Era – Minimally Invasive Surgery for Early Gastric Cancer and Adjuvant Surgery for Metastatic Gastric Cancer. PAT. Karger Publishers; 2011;78:343–52. ID - ref10 ER - TY - STD TI - Suzuki T, Tanabe K, Taomoto J, Yamamoto H, Tokumoto N, Yoshida K, et al. Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett. Spandidos Publications; 2010;1:743–7. ID - ref11 ER - TY - STD TI - Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. Springer-Verlag; 2009;16:3227–36. ID - ref12 ER - TY - STD TI - Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol. Springer-Verlag; 2011;69:407–13. ID - ref13 ER - TY - STD TI - Janjigian YY, Riches JC, Ku GY, Imtiaz T, Capanu M, Chou JF, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab [abstract]. J Clin Oncol. 2015;33(3 Suppl):63. ID - ref14 ER - TY - STD TI - Yonemura Y, Endo Y, Obata T, Sasaki T. Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites. Cancer Science. Wiley/Blackwell (10.1111); 2007;98:11–8. ID - ref15 ER - TY - STD TI - Osugi ​H, Takada N, Takemura M, Kaseno S, Lee S, Ueno M, Tanaka Y, Fukuhara K, Fujiwara Y, Kinoshita H (2002) Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination. Oncology Reports ID - ref16 ER - TY - STD TI - ​Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2006;59:795–805. ID - ref17 ER - TY - STD TI - ​Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol. 2009;17:14–7. ID - ref18 ER - TY - STD TI - Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, et al. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2012;16:84–93. ID - ref19 ER - TY - STD TI - Deguchi Y, Okabe H, Oshima N, Hisamori S, Minamiguchi S, Muto M, et al. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma. Gastric Cancer. 2017;20:416–27. ID - ref20 ER -